Research programme: bispecific antibodies - Zymeworks/Merck & Co
Alternative Names: Azymetric™ scaffold; EFECT™Latest Information Update: 01 Mar 2023
At a glance
- Originator Zymeworks
- Developer Merck & Co; Zymeworks
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 01 Mar 2023 Preclinical trials in Unspecified in Canada (Parenteral) prior to March 2023 (Zymeworks website, March 2023)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Autoimmune-disorders in Canada (Parenteral)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in Canada (Parenteral)